Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
Do you utilize tumor treating fields in patients with anaplastic Pleomorphic Xanthoastrocytoma PXA III?
Related Questions
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
Are you offering Lutathera for multiple recurrent meningiomas?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do you approach anti-seizure medication management when it was started by another team for a seizure-naive patient before/after craniotomy for a tumor?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
What experience do you have with paralysis or myasthenia like symptoms developing on Temozolomide?
